Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing
| Autor: | Miłosz Regulski, Katarzyna Regulska, Bartosz Karolak, Beata Stanisz, Marek Murias |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Sympathetic nervous system Sympathetic Nervous System medicine.medical_treatment Mevalonic Acid Bioinformatics Cardiac Glycosides Renin-Angiotensin System 03 medical and health sciences 0302 clinical medicine Coagulation cascade Neoplasms Drug Discovery medicine Animals Humans Repurposing Pharmacology business.industry Drug Repositioning Anticoagulants Cardiovascular Agents Cancer treatment Drug repositioning 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Cancer management Mevalonate pathway Hydroxymethylglutaryl-CoA Reductase Inhibitors business Adjuvant |
| Zdroj: | Drug Discovery Today. 24:1059-1065 |
| ISSN: | 1359-6446 |
| Popis: | Research on the concept of biological overlap between cardiovascular and oncological diseases is gaining momentum. In fact, in both conditions, the malfunction of common regulatory mechanisms, such as the renin-angiotensin system (RAS), sympathetic nervous system (SNS), coagulation cascade, sodium-potassium ATP-ases, and mevalonate pathway, occurs. Thus, targeting these mechanisms with well-known cardiology drugs, including angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), β-adrenergic receptor blockers, statins, cardiac glycosides (CGs), and low-molecular-weight heparins (LMWHs), could be a novel, promising adjuvant strategy in cancer management. Thus, here we discuss the idea of repurposing cardiology drugs in oncology based on available preclinical and clinical data. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect